We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Anti-Influenza Drug Targets Nucleoprotein

By LabMedica International staff writers
Posted on 23 Jun 2010
Drug developers have identified a low molecular weight compound, nucleozin, which was shown to be a potent antiviral agent with the potential to become a primary drug for treating influenza infections.

Investigators at the University of Hong Kong (China) screened a chemical library of more than 50,000 compounds for those with anti-influenza activity. More...
Ultimately, they selected nucleozin for further characterization, as it was highly potent in cell culture and also in mice infected with the pathogenic influenza virus H5N1.

In the influenza virus, nucleoprotein plays critical roles in RNA replication and genome assembly, and nucleozin was shown to aggregate nucleoprotein and prevent its transport into the nucleus. This blocked replication of H1N1, H3N2, and H5N1 viruses in cell culture experiments and protected mice against H5N1. These findings were published in the May 30, 2010, online edition of the journal Nature Biotechnology.

First author Dr. Richard Y. Kao, professor of microbiology at the University Honk Kong, said, "Nucleozin is highly potent in cell culture and also in mice infected with the highly pathogenic influenza virus H5N1. Scientists could now use nucleoprotein as a target to develop antiviral therapeutics for the treatment of influenza infection.”

Related Links:
University of Hong Kong




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.